【结 构 式】 |
【分子编号】11919 【品名】methyl 3-methoxy-4-methylbenzoate 【CA登记号】3556-83-0 |
【 分 子 式 】C10H12O3 【 分 子 量 】180.20348 【元素组成】C 66.65% H 6.71% O 26.64% |
合成路线1
该中间体在本合成路线中的序号:(I)Bromination of methyl 3-methoxy-4-methylbenzoate (I) with N-bromosuccinimide in the presence of catalytic amounts of 2,2'-azabisisobutyronitrile in chlorobenzene yields benzylic bromide (II). This compound is coupled with 5-nitroindole via treatment with Ag2CO3 in toluene to afford methyl 4-(5-nitroindol-3-ylmethyl)-3-methoxybenzoate (III). N-Methylation of ester (III), using NaH and MeI in DMF, followed by hydrolysis with NaOH in aqueous THF, affords 4-(5-nitro-1-methylindol-3-ylmethyl)-3-methoxybenzoic acid (IV). Conversion of acid (IV) to the sulfonimide derivative (V) is achieved by sequentially treating (IV) with: (i) SOCl2 plus a catalytic amount of DMF in dichloromethane and (ii) o-tolylsulfonamide and 4-(N,N-dimethylamino)pyridine (DMAP). This intermediate sulfonimide is isolated as the DMAP salt (V), which is converted to ICI 204219 via treatment with H2 over Pd/C in alkaline aqueous methoxyethanol, followed by acylation with cyclopentylchloroformate.
【1】 Brown, F.J.; Bernstein, P.R.; Yee, Y.K.; Matassa, V.G. (AstraZeneca LP); Heterocyclic amide derivs. AU 8656164; EP 0199543; EP 0220066; ES 8801787; ES 8802220; ES 8802493; ES 8802494; JP 1987093274; JP 1987099359; US 4859692; US 4918094; US 5030643; US 5049576; US 5179112 . |
【2】 Edwards, M.P.; Sherwood, J.D. (AstraZeneca plc); A physical form of N-[4-[5-(cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compsns. containing it. EP 0490649; US 5294636 . |
【3】 Aharony, D.; Snyder, D.W.; Keith, R.A.; Shapiro, H.S.; Matassa, V.G.; Maduskuie, T.P. Jr.; Hesp, B.; Krell, R.D.; Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles. J Med Chem 1990, 33, 6, 1781. |
【4】 Bernstein, P.R.; Accolate. Drugs Fut 1994, 19, 3, 217. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
26919 | 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-amine | C14H17N3 | 详情 | 详情 | ||
(I) | 11919 | methyl 3-methoxy-4-methylbenzoate | 3556-83-0 | C10H12O3 | 详情 | 详情 |
(II) | 11920 | methyl 4-(bromomethyl)-3-methoxybenzoate; 4-(Bromomethyl)-3-methoxy benzoic acid methyl ester | C10H11BrO3 | 详情 | 详情 | |
(III) | 11921 | methyl 3-methoxy-4-[(5-nitro-1H-indol-3-yl)methyl]benzoate | C18H16N2O5 | 详情 | 详情 | |
(IV) | 11922 | 3-Methoxy-4-[(1-methyl-5-nitro-1H-indol-3-yl)methyl]benzoic acid | C18H16N2O5 | 详情 | 详情 | |
(V) | 11923 | 3-Methoxy-4-(1-methyl-5-nitro-1H-indol-3-ylmethyl)-N-(2-methylphenylsulfonyl)benzamide 4-(dimethylamino)pyridine salt | C32H33N5O6S | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号:(I)Radical bromination of methyl 3-methoxy-4-methylbenzoate (I) using N-bromosuccinimide and azobisisobutyronitrile gave benzyl bromide (II), which was treated with pyrrolidine to afford the tertiary amine (III). Hydrolysis of the methyl ester group of (III) with LiOH provided carboxylic acid (IV), which was converted to acid chloride (V) upon treatment with SOCl2.
【1】 Antithrombotic diamines. EP 0863755; US 6025382; WO 9725033 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(A) | 11376 | Pyrrolidine | 123-75-1 | C4H9N | 详情 | 详情 |
(I) | 11919 | methyl 3-methoxy-4-methylbenzoate | 3556-83-0 | C10H12O3 | 详情 | 详情 |
(II) | 11920 | methyl 4-(bromomethyl)-3-methoxybenzoate; 4-(Bromomethyl)-3-methoxy benzoic acid methyl ester | C10H11BrO3 | 详情 | 详情 | |
(III) | 31412 | methyl 3-methoxy-4-(1-pyrrolidinylmethyl)benzoate | C14H19NO3 | 详情 | 详情 | |
(IV) | 31413 | 3-methoxy-4-(1-pyrrolidinylmethyl)benzoic acid | C13H17NO3 | 详情 | 详情 | |
(V) | 31414 | 3-methoxy-4-(1-pyrrolidinylmethyl)benzoyl chloride | C13H16ClNO2 | 详情 | 详情 |